AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22363068 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (675 mg/m2 i.v. over 90 minutes on days 1 and 8) in combination with docetaxel (75 mg/m2 i.v. over 1 hour on day 8) every 21 days; all patients received filgrastim or pegfilgrastim.
Number of subjects: 53
Study 22363582 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-MVA AMA1
Number of subjects: 16
Study 22364114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-determined physical activity (steps/day)
Number of subjects: 327
Study 22365026 — intervention group
Group type: EXPERIMENTAL
Intervention: Monozygotic (MZ) twins
Number of subjects: 514
Study 22365026 — intervention group
Group type: COMPARATOR
Intervention: Dizygotic (DZ) twins
Number of subjects: 514
Study 22365026 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 514
Study 22365026 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors
Number of subjects: 514
Study 22365026 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic factors
Number of subjects: 514
Study 22365807 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American youth with LOC eating
Number of subjects: 185
Study 22365807 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American youth without LOC eating
Number of subjects: 185
Study 22365807 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian youth with LOC eating
Number of subjects: 185
Study 22365807 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian youth without LOC eating
Number of subjects: 185
Study 22365807 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy consumption for African-American youth
Number of subjects: 185
Study 22365807 — intervention group
Group type: COMPARATOR
Intervention: Prevalence of LOC episodes
Number of subjects: 185
Study 22367574 — intervention group
Group type: EXPERIMENTAL
Intervention: Edema index more than 0.390 (n=44)
Number of subjects: 112
Study 22367574 — intervention group
Group type: COMPARATOR
Intervention: Edema index of 0.390 or less (n=68)
Number of subjects: 112
Study 22367574 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing the edema index in high-risk patients
Number of subjects: 112
Study 22367707 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with panitumumab (gemcitabine 1000 mg/m², oxaliplatin 60 mg/m², panitumumab 6 mg/kg i.v. every 2 weeks followed by capecitabine 1000 mg/m² for 7 days)
Number of subjects: 46
Study 22368272 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRLF2 expression
Number of subjects: 1061
Study 22368272 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD)
Number of subjects: 1061
Study 22368272 — intervention group
Group type: EXPERIMENTAL
Intervention: IKZF1 lesions
Number of subjects: 1061
Study 22368272 — intervention group
Group type: COMPARATOR
Intervention: CRLF2 genomic lesions
Number of subjects: 1061
Study 22368281 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 2702
Study 22368281 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy
Number of subjects: 2702
Study 22369270 — intervention group
Group type: EXPERIMENTAL
Intervention: High disease activity group (SLEDAI > 10)
Number of subjects: 124
Study 22369270 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine treatment
Number of subjects: 124
Study 22369270 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids treatment
Number of subjects: 124
Study 22369270 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal echocardiographic findings
Number of subjects: 124
Study 22371186 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 22371186 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration rivaroxaban
Number of subjects: 0
Study 22371427 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg once daily (maximum-tolerated dose)
Number of subjects: 21
Study 22371427 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (various doses: 80, 160, 240, 320 mg)
Number of subjects: 21
Study 22371427 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (various doses)
Number of subjects: 21
Study 22371819 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based care for 1-2 weeks
Number of subjects: 0
Study 22371819 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based home care
Number of subjects: 0
Study 22371878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg once daily
Number of subjects: 118
Study 22372628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day (with dosage adjustments allowed between 100-800 mg/day)
Number of subjects: 308
Study 22372628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day
Number of subjects: 308
Study 22372628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide monotherapy for ≥12 months
Number of subjects: 308
Study 22372628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide for ≥2 years
Number of subjects: 308
Study 22372628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide treatment
Number of subjects: 308
Study 22373120 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 1425
Study 22373120 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 1425
Study 22373120 — intervention group
Group type: EXPERIMENTAL
Intervention: MAXICU ≥ 39.5°C
Number of subjects: 1425
Study 22373120 — intervention group
Group type: COMPARATOR
Intervention: MAXICU < 39.5°C
Number of subjects: 1425
Study 22373658 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme hydrolysis using commercial sulfatases
Number of subjects: 0
Study 22373658 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased enzyme quantity, optimized pH, and alternative enzyme sources
Number of subjects: 0
Study 22373658 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature assessment
Number of subjects: 0
Study 22373658 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantification methods for epicatechin
Number of subjects: 0
Study 22373834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (10 mg/kg intravenously on Day 8)
Number of subjects: 0
Study 22373834 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (10 - 25 mg orally on Days 1, 8, 15, 22, 29, 36, and 43)
Number of subjects: 0
Study 22373835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 5 mg/d
Number of subjects: 10
Study 22373835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 25 mg/d
Number of subjects: 10
Study 22373835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/d
Number of subjects: 10
Study 22373905 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management strategy
Number of subjects: 9406
Study 22373905 — intervention group
Group type: COMPARATOR
Intervention: Revascularization
Number of subjects: 9406
Study 22373906 — intervention group
Group type: EXPERIMENTAL
Intervention: ANGELS of AF intervention (specific reports on stroke risk factors and antithrombotic therapy)
Number of subjects: 3438
Study 22373906 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific reports provided)
Number of subjects: 3438
Study 22374129 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with MetS (n=34)
Number of subjects: 58
Study 22374129 — intervention group
Group type: COMPARATOR
Intervention: Men without MetS (n=24)
Number of subjects: 58
Study 22374129 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with lower BDNF levels (n not specified)
Number of subjects: 58
Study 22374129 — intervention group
Group type: COMPARATOR
Intervention: Men with higher BDNF levels (n not specified)
Number of subjects: 58
Study 22374129 — intervention group
Group type: EXPERIMENTAL
Intervention: Men without diabetes (n not specified)
Number of subjects: 58
Study 22374920 — intervention group
Group type: EXPERIMENTAL
Intervention: AeriSeal emphysematous lung sealant (ELS)
Number of subjects: 28
Study 22377126 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with bevacizumab, trastuzumab, and chemotherapy (fluorouracil, epirubicin, cyclophosphamide, and bevacizumab for cycles 1-4; docetaxel, bevacizumab, and trastuzumab for cycles 5-8)
Number of subjects: 52
Study 22377126 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with bevacizumab, trastuzumab, and chemotherapy
Number of subjects: 52
Study 22378109 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous-deficient dry eye (ADDE) classified with Schirmer values of <7 mm and MGD grades of ≤5
Number of subjects: 299
Study 22378109 — intervention group
Group type: EXPERIMENTAL
Intervention: Meibomian gland dysfunction (MGD) classified with MGD grades of >5 and Schirmer values of ≥7 mm
Number of subjects: 299
Study 22378109 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed (hybrid) category with low Schirmer value of <7 and evidence of MGD with a grade >5
Number of subjects: 299
Study 22378109 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall DED patients
Number of subjects: 299
Study 22378109 — intervention group
Group type: EXPERIMENTAL
Intervention: Other clinical signs of DED without overt evidence of MGD or ADDE
Number of subjects: 299
Study 22378328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement, education, promotion of existing clinical services, and social support (24-week intervention)
Number of subjects: 73
Study 22378328 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no intervention)
Number of subjects: 73
Study 22378730 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pregravid BMI
Number of subjects: 170
Study 22378730 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravid hyperglycemia
Number of subjects: 170
Study 22378730 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance
Number of subjects: 170
Study 22378730 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower insulin sensitivity
Number of subjects: 170
Study 22378730 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum adiponectin
Number of subjects: 170
Study 22378730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 170
Study 22378730 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of gestation
Number of subjects: 170
Study 22378730 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscheduled cesarean delivery
Number of subjects: 170
Study 22378848 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 619
Study 22378848 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 4 (Q4) based on CD33 expression
Number of subjects: 619
Study 22378848 — intervention group
Group type: EXPERIMENTAL
Intervention: High CD33 expression
Number of subjects: 619
Study 22379151 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide treatment
Number of subjects: 0
Study 22381092 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% ropivacaine bilaterally into the TAP
Number of subjects: 20
Study 22381365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with 500 mg vitamin C, 400 IU vitamin E, 15 mg β-carotene, 80 mg zinc oxide, and 2 mg cupric oxide per day for 5 days.
Number of subjects: 19
Study 22381365 — intervention group
Group type: COMPARATOR
Intervention: Non-AMD controls
Number of subjects: 19
Study 22382879 — intervention group
Group type: EXPERIMENTAL
Intervention: linifanib 0.10 mg/kg
Number of subjects: 18
Study 22382879 — intervention group
Group type: EXPERIMENTAL
Intervention: linifanib 0.25 mg/kg
Number of subjects: 18
Study 22382879 — intervention group
Group type: EXPERIMENTAL
Intervention: linifanib
Number of subjects: 18
Study 22383693 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary IL-18
Number of subjects: 380
Study 22383693 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary albumin to creatinine ratio (ACR)
Number of subjects: 380
Study 22383693 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma neutrophil gelatinase-associated lipocalin (NGAL)
Number of subjects: 380
Study 22383693 — intervention group
Group type: COMPARATOR
Intervention: Clinical model alone
Number of subjects: 380
Study 22383790 — intervention group
Group type: EXPERIMENTAL
Intervention: obatoclax mesylate (GX15-070)
Number of subjects: 0
Study 22383795 — intervention group
Group type: EXPERIMENTAL
Intervention: PD0332991
Number of subjects: 17
Study 22383800 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-protein biomarker panel measured at GVHD onset, day 14, and day 28
Number of subjects: 0
Study 22383800 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-protein biomarker panel
Number of subjects: 0
Study 22384093 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous nonmyeloablative hematopoietic stem cell transplantation (AHST)
Number of subjects: 9
Study 22386040 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily home QT interval monitoring using HeartView™ ECG recorder for 6 months
Number of subjects: 325
Study 22386040 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily home QT interval monitoring
Number of subjects: 325
Study 22388106 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan
Number of subjects: 3525
Study 22388106 — intervention group
Group type: COMPARATOR
Intervention: Non-alvimopan
Number of subjects: 3525
Study 22388170 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 22388706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil bolus, starting at 0.15 μg/kg
Number of subjects: 25
Study 22388706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil bolus
Number of subjects: 25
Study 22388706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive sufentanil bolus
Number of subjects: 25
Study 22388712 — intervention group
Group type: EXPERIMENTAL
Intervention: IDO-reactive CD8(+) T cells
Number of subjects: 0
Study 22388712 — intervention group
Group type: EXPERIMENTAL
Intervention: IDO-specific T cells
Number of subjects: 0
Study 22390818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid challenge with hydroxyethyl starch
Number of subjects: 36
Study 22393174 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine insulin-free cow's milk formula (CMF)
Number of subjects: 1113
Study 22393174 — intervention group
Group type: COMPARATOR
Intervention: Whey-based hydrolyzed formula (WHF)
Number of subjects: 1113
Study 22393174 — intervention group
Group type: COMPARATOR
Intervention: Whey-based FINDIA formula (essentially free of bovine insulin)
Number of subjects: 1113
Study 22394984 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.3 mg/m(2) for normal function; 0.5 mg/m(2) for severe impairment; 0.7 mg/m(2) for moderate impairment; 1.0 mg/m(2) for mild impairment.
Number of subjects: 61
Study 22394984 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib at 0.7 mg/m(2) for moderate impairment; 0.5 mg/m(2) for severe impairment.
Number of subjects: 61
Study 22394992 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM(197)
Number of subjects: 382
Study 22394992 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC priming and MenACWY-CRM(197) booster
Number of subjects: 382
Study 22394992 — intervention group
Group type: COMPARATOR
Intervention: MenC vaccine (control)
Number of subjects: 382
Study 22396223 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed casein formula supplemented with Lactobacillus rhamnosus GG (EHF-LGG)
Number of subjects: 31
Study 22396223 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolysed casein formula (EHF)
Number of subjects: 31
Study 22396313 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood gene expression score (GES) for obstructive CAD likelihood
Number of subjects: 1160
Study 22396581 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel-treated patients
Number of subjects: 180
Study 22396585 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone with incident diabetes
Number of subjects: 22418
Study 22396585 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine or Lisinopril with incident diabetes
Number of subjects: 22418
Study 22396585 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with incident diabetes
Number of subjects: 22418
Study 22396585 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 22418
Study 22397652 — intervention group
Group type: EXPERIMENTAL
Intervention: ENB-0040
Number of subjects: 11
Study 22397748 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated ultrasound-guided transvaginal ovarian interstitial laser treatment
Number of subjects: 27
Study 22398432 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental treadmill test for VO2max assessment
Number of subjects: 240
Study 22398432 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical, behavioral, and motivational factors
Number of subjects: 240
Study 22398655 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg once daily
Number of subjects: 1281
Study 22398655 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily
Number of subjects: 1281
Study 22398655 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban with 50% dose reductions for patients with moderate renal impairment or receiving concomitant strong P-glycoprotein (P-gp) inhibitors
Number of subjects: 1281
Study 22399502 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal vein sampling (AVS)
Number of subjects: 2604
Study 22399525 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL mangosteen juice with a high-fat breakfast
Number of subjects: 10
Study 22401488 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (added to mood stabilizers and/or atypical antipsychotics)
Number of subjects: 221
Study 22402037 — intervention group
Group type: EXPERIMENTAL
Intervention: PADRE-CMV vaccine with PF03512676 adjuvant
Number of subjects: 58
Study 22402037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus-CMV vaccine with PF03512676 adjuvant
Number of subjects: 58
Study 22402037 — intervention group
Group type: COMPARATOR
Intervention: CMV peptide vaccines without PF03512676 adjuvant
Number of subjects: 58
Study 22403000 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 54
Study 22403632 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary trans fatty acids (dTFA)
Number of subjects: 945
Study 22404128 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete excision of endometriosis, including vaginal resection
Number of subjects: 22
Study 22405335 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-active HAART including lamivudine and/or tenofovir
Number of subjects: 36
Study 22406240 — intervention group
Group type: EXPERIMENTAL
Intervention: OPRM1 SNPs (rs1074287, rs6912029, rs12209447, rs510769, rs3798676, rs7748401, rs495491, rs10457090, rs589046, rs3778152, rs563649, rs2075572)
Number of subjects: 366
Study 22406240 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of MMT patients with positive urine morphine test
Number of subjects: 366
Study 22406240 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of MMT patients not using benzodiazepine hypnotics
Number of subjects: 366
Study 22406298 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial knee pain
Number of subjects: 240
Study 22406298 — intervention group
Group type: COMPARATOR
Intervention: Anterior knee pain
Number of subjects: 240
Study 22408206 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval aerobic knee extensor exercise training (6 weeks, 3 days per week)
Number of subjects: 7
Study 22408206 — intervention group
Group type: COMPARATOR
Intervention: Control group (five age-matched healthy individuals)
Number of subjects: 7
Study 22408210 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated subjects with SDB (RDI >15 events · h(-1))
Number of subjects: 519
Study 22408210 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated subjects without SDB (RDI ≤ 15 events · h(-1))
Number of subjects: 519
Study 22408210 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall untreated subjects
Number of subjects: 519
Study 22408210 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-SDB group
Number of subjects: 519
Study 22408210 — intervention group
Group type: EXPERIMENTAL
Intervention: SDB group
Number of subjects: 519
Study 22410555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian regression model incorporating risk factors and progressive optic disc damage
Number of subjects: 250
Study 22410555 — intervention group
Group type: COMPARATOR
Intervention: Ordinary least squares (OLS) linear regression
Number of subjects: 250
Study 22411933 — intervention group
Group type: EXPERIMENTAL
Intervention: high-exposure arm (guideline-based therapy supplemented with antibiotic escalation)
Number of subjects: 1200
Study 22411933 — intervention group
Group type: COMPARATOR
Intervention: standard-exposure arm (guideline-based therapy)
Number of subjects: 1200
Study 22411933 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam
Number of subjects: 1200
Study 22411933 — intervention group
Group type: EXPERIMENTAL
Intervention: meropenem
Number of subjects: 1200
Study 22411933 — intervention group
Group type: EXPERIMENTAL
Intervention: after discontinuing piperacillin/tazobactam
Number of subjects: 1200
Study 22411933 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <60 ml/min/1.73 m(2) at entry
Number of subjects: 1200
Study 22411933 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <60 ml/min/1.73 m(2) at last day of follow-up
Number of subjects: 1200
Study 22412114 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 22412114 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard care not specified)
Number of subjects: 0
Study 22415795 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 50 mg
Number of subjects: 12
Study 22415795 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 125 mg
Number of subjects: 12
Study 22415795 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 175 mg
Number of subjects: 12
Study 22415795 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib (all doses)
Number of subjects: 12
Study 22415951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraspinal infusion of autologous bone marrow mononuclear cells (BMNCs)
Number of subjects: 11
Study 22416054 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 1794